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Our previous studies have shown the ability of human CD34+
cells to stimulate T cell alloproliferative responses in-vitro.
Here, we investigated the anti-CD34 T cell alloreactivity in-
vivo by co-transplanting human CD34+ cells and allogeneic T
cells of an incompatible individual into NSG mice. Human
CD34+ cells (2x105/animal) were transplanted with alloge-
neic T cells at different ratios ranging from 1:50 to 1:0.5, or
without as a control. Engraftment of human CD 45+ cells was
analyzed by ﬂow cytometry at 1, 2, 4, or 8 weeks. Marrow
engraftment of human CD45+cells was signiﬁcantly
decreased in mice transplanted at any CD34:T cell ratio
compared to control mice that did not receive T cells.
Transplantation of T cells resulted in graft failure since >98%
of human CD45+ cells in the marrow and spleen of NSG mice
were CD3+. A normal CD4:CD8 T cell ratio was detected and
CD4+ cells were mostly CD45RA+. Mice transplanted with
CD34+ and allogeneic T cells at 1:1 ratio were sacriﬁced at 1,
2, or 4 weeks to analyze the kinetics of human cell engraft-
ment in the bone marrow and spleen. At 2 weeks post
transplant, the bone marrow showed CD34-derived myeloid
cells, whereas the spleen showed only allo-T cells. At 4
weeks, all myeloid cells had been rejected and only T cells
were detected both in the bonemarrow and spleen. Based on
our previous in-vitro studies showing that T cell allor-
eactivity against CD34+ cells is mainly due to B7:CD28 cos-
timulatory activation, we injected the mice with CTLA4-Ig
(Abatacept, Bristol Myers Squibb) from d-1 to d+28 post
transplantation of CD34+ and allogeneic T cells. We found
that treatment of mice with CTLA4-Ig prevented rejection
and allowed CD34+ cells to fully engraft the marrow of NSG
mice at 4 weeks with an overall 13 + 7% engraftment of hu-
man CD45+ marrow cells (n¼5). These included 53 + 9%
myeloid CD33+ cells, 22 + 3% CD14+ monocytes, 7 + 2% CD1c
myeloid dendritic cells, and 4 + 1% CD34+ cells while CD 19 B
cells were only 3% and CD3+ T cells 0.5 + 1%. Persistent
myeloid engraftment was found at d+56 after stopping
CTLA4-Ig on d+28. Here we demonstrate that costimulatory
blockadewith CTLA4-Ig can prevent Tcell mediated rejection
of incompatible human CD34+ stem cells. We also show that
the NSGmodel can be utilized to test in-vivo immunotherapy
strategies aimed at engrafting human stem cells across HLA
barriers. These results will prompt the design of future
clinical trials of CD34+ cell transplantation for patients with
severe non-malignant disorders, such as sickle cell anemia,
thalassemia, immunodeﬁciencies or aplastic anemia.Figure 1. Overall Survival by HCT-CI Score379
Hematopoietic Cell Transplant Co-Morbidity Index
(HCT-CI): Ability to Predict Outcomes in Haploidentical
(HI) Hematopoietic Stem Cell Transplantation (HSCT)
Neil D. Palmisiano, Sameh Gaballa, Onder Alpdogan,
Matthew Carabasi, Joanne Filicko, Margaret Kasner,
Ubaldo Martinez, John L. Wagner, Mark Weiss,
Neal Flomenberg, Dolores Grosso. Department of Medical
Oncology, Kimmel Cancer Center, Thomas Jefferson University,
Philadelphia, PA
Introduction:We developed a 2 step approach to HI HSCT in
which a ﬁxed dose of allogeneic T cells are infused after
reduced intensity (RIC) or myeloablative conditioning (HSCT
step 1). After 2-3 days, cyclophosphamide (CY) 60 mg/kg/d x
2 is given to establish bidirectional tolerance. One day after
the CY, a CD 34 selected stem cell product is infused (HSCT
step 2). This approach has been associated with a lowincidence of non-relapse mortality (NRM) resulting in a
signiﬁcant improvement in overall survival (OS) in patients
(pts) undergoing HI HSCT at our institution. We used the
HCT-CI as one of several tools to establish an optimal
screening process for this new type of HSCT. Now with
substantial numbers of pts treated, we examined the pre-
dictability of this tool in pts undergoing the 2 step HI HSCT.
Methods: We retrospectively analyzed pts treated on the 2-
step HI protocols who had HCT-CI scores calculated for
screening purposes. Pts were divided into 3 previously
described risk groups: 0, 1-2, and  3. Survival data was
calculated according to Kaplan-Meier methods.
Results: We identiﬁed 157 pts; 61 female, 96 male, median
age 55 (range 19-78), 34% undergoing RIC HSCT with com-
plete HCT-CI data whowere transplanted from 2007 through
2013. As a whole, 23 pts (15%) had a HCT-CI score of 0, 55
(35%) had a score of 1-2, and 79 (50%) had a score of  3. A
HCT-CI score of 0 was associated with a signiﬁcantly
increased OS (p¼0.039) withmedian survival not reached for
HCT-CI score 0 or score 1-2 versus 21 months with score  3
(ﬁg. 1). We also examined the predictability of the HCT-CI on
OS of pts with (54%) versus without (46%) disease at HSCT,
and found that differences (ﬁgures 2-3) between HCT-CI
groups were limited to pts with disease at time of HSCT
(p¼0.003 vs p¼0.765). Twenty nine of 157 (19 %) died of
NRM: 3 pts (10%) in the 0, 8 (28%) in the 1-2, and 18 (62%) in
the  3 score groups respectively.
Conclusions: Analysis of HCT-CI as a screening tool in the 2
step HI HSCT suggests its ability to correctly identify pts in
the lowest score category as being at decreased risk for
mortality. Predictability of OS in pts with higher scores was
limited to those with disease at the time of HSCT. There was
also a suggestion that higher scores correlated with
increased rates of NRM. Of note, both the percent of pts with
3 points and their OS was higher in the 2 step group than
what was reported by Sorror in 2005. While we believe this
is due in part to the low NRM associated with the 2 step
method even in higher risk groups, we also note that more of
the 2 step pts had 2-3 points for low PFTs (80% vs 33%). This
indicates that the calculation of pulmonary function as
measured at our institution may have inﬂated the high risk
numbers, affecting optimal use of the tool. Next steps include
assessing PFT methodology as it affects the HCT-CI as well as
the utility of other comorbidity indices in conjunction with
the HCT-CI, including Karnofsky performance score.
